InflaRx N.V. share price logo

InflaRx N.V.

NASDAQ: IFRX

Small Cap

$2.45

-0.05

(-2.00%)

as on

InflaRx N.V. Stock Performance

as on May 13, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $2.31
    $2.55
    downward going graph

    5.71%

    Downside

    4.08%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $0.71
    $2.95
    downward going graph

    70.97%

    Downside

    20.36%

    Upside

    downward going graph

InflaRx N.V. share price movements today

Previous Close
$2.50
Open
$2.50
Volume
3.0M
Day's Low - High
$2.31 - $2.55
52 Week Low - High
$0.71 - $2.95

InflaRx N.V. Historical Returns

1 Month Return
+ 150 %
3 Month Return
+ 200.73 %
1 Year Return
+ 49.7 %
3 Year Return
-50.98 %
5 Year Return
-12.28 %

InflaRx N.V. Stock Fundamentals & Key Indicators

Check InflaRx N.V. market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$186.5M

EPS (TTM)

-0.6625

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

0

PEG Ratio

0

EBITDA

-42.4M

Revenue (TTM)

29.3K

Profit Margin

0.00%

Return On Equity TTM

-79.94%

InflaRx N.V. vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of InflaRx N.V. with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %
InflaRx N.V. image
InflaRx N.V.
BUY$186.5M-12.28%NA0.00%
Alnylam Pharmaceuticals Inc image
Alnylam Pharmaceuticals Inc
BUY$39.4B113.59%74.1312.55%
BeiGene, Ltd. image
BeiGene, Ltd.
NA$32.2BNA70.468.94%
Vertex Pharmaceuticals Inc image
Vertex Pharmaceuticals Inc
BUY$109.1B104.61%25.5135.51%
Regeneron Pharmaceuticals Inc image
Regeneron Pharmaceuticals Inc
BUY$74.9B40.55%17.4529.65%

Stock Returns calculator for InflaRx N.V. Stock including INR - Dollar returns

The InflaRx N.V. stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

InflaRx N.V. investment value today

Current value as on today

₹1,65,257

Returns

₹65,257

(+65.26%)

Returns from InflaRx N.V. Stock

₹46,707 (+46.71%)

Dollar Impact

₹18,551 (+18.55%)

Analyst Recommendation on InflaRx N.V. Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for InflaRx N.V.. Average target price of $8.77

InflaRx N.V. Share Price Target

Get share price movements and forecasts by analysts on InflaRx N.V..

What analysts predicted

72.06%UPSIDE

Target Price

$8.77

Current Price

$2.45

Analyzed by

11 Analysts

Target

$8.77

InflaRx N.V. target price $8.77, a slight upside of 72.06% compared to current price of $2.45. According to 11 analysts rating.

Indian Investors' Interest in InflaRx N.V. Stock

Search interest for InflaRx N.V. Stock has increased by 346% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:346% versus previous 30 day period

InflaRx N.V. Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Total Revenue
0
0
0
0
0
-
0
0
0
Gross Profit
0
0
0
0
-2
0
-2
0
-5
Operating Income
-12
-12
-15
-15
-9
-13
-12
-9
-13
EBITDA
-15
-9
-12
-17
-4
-8
-14
-12
-13
Interest Expense
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
Income Before Tax
-15
-9
-12
-17
-5
-8
-14
-12
-8
Income Tax Expense
0
0
0
0
-
-
-
0
0
Net Income
-16
-9
-13
-17
-5
-8
-14
-12
-8
Net Profit Margin
-697154.59%
-26798.11%
-217803.07%
-14092.87%
1208456.74%
0.00%
-36559.83%
-51452.32%
25196.92%

InflaRx N.V. Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
-
0
-
-
-
-
-
0
0
0
Gross Profit
0
0
0
0
0
0
0
0
-3
-7
Operating Income
-6
-19
-37
-63
-38
-56
-55
-44
-53
-48
EBITDA
-7
-19
-42
-58
-37
-53
-30
-42
-45
-48
Interest Expense
1
2
-
0
0
0
0
0
0
0
Depreciation
-
0
0
0
0
0
0
0
0
0
Income Before Tax
-8
-24
-29
-59
-38
-53
-30
-42
-46
-43
Income Tax Expense
1
2
7
-3
0
0
-2
0
0
0
Net Income
-9
-28
-33
-66
-47
-60
-32
-46
-48
-43
Net Profit Margin
0.00%
-10492.64%
0.00%
0.00%
0.00%
0.00%
0.00%
-67630.69%
-27784.96%
-155584.20%

InflaRx N.V. Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-9
-13
-17
-5
-8
-14
-12
-8
-5
Operating Cash Flow
-14
-12
-9
-11
-14
-7
-9
-4
-7
Investing Cash Flow
26
5
17
1
17
-24
2
7
6
Financing Cash Flow
0
0
0
0
27
0
0
6
0
Change in Cash
12
-5
7
-7
28
-34
-6
9
8

InflaRx N.V. Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-24
-29
-53
-33
-45
-29
-42
-46
-43
Operating Cash Flow
-12
-23
-43
-36
-39
-33
-37
-48
-33
Investing Cash Flow
0
-99
20
21
-25
19
-17
52
3
Financing Cash Flow
108
49
0
9
61
1
52
0
32
Change in Cash
94
-67
-22
-7
0
-9
-3
5
0

Global Institutional Holdings in InflaRx N.V.

Funds
Holdings
Squarepoint Ops LLC
0.45%
DCF Advisers, LLC
0.22%
RA Capital Management, LLC
2.91%
UBS O'Connor LLC
0.22%
Eversept Partners, LP
2.43%
See all

Insights on InflaRx N.V.

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 month, IFRX stock has moved up by 133.6%

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, IFRX has outperformed top 5 stocks with highest market-cap in its industry

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 30.4% return, outperforming this stock by 81.4%

About InflaRx N.V.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
OrganisationInflaRx N.V.
HeadquartersWinzerlaer Str. 2, Jena, Germany, 07745
IndustryBiotechnology
CEOProf. Niels C. Riedemann M.D., Ph.D.
E-voting on sharesClick here to vote

Key Management of InflaRx N.V.

Name

Title

Prof. Niels C. Riedemann M.D., Ph.D.

Co-Founder, CEO & Executive Director

Prof. Renfeng Guo M.D.

Co-Founder, Chief Scientific Officer & Executive Director

Dr. Thomas Taapken Ph.D.

Chief Financial Officer

Ms. Derval O'Carroll

Senior VP and Global Head of Regulatory Affairs & Compliance

Dr. Camilla Chong M.D.

Chief Medical Officer

Mr. Jan Medina CFA

Head of Investor Relations & VP

Mr. Christian Schmid

VP and Head of Legal Affairs & General Counsel

FAQs

What is InflaRx N.V. share price today?

InflaRx N.V. share price today is $2.45 as on at the close of the market. InflaRx N.V. share today touched a day high of $2.55 and a low of $2.31.

What is the 52 week high and 52 week low for InflaRx N.V. share?

InflaRx N.V. share touched a 52 week high of $2.95 on and a 52 week low of $0.71 on . InflaRx N.V. stock price today i.e. is closed at $2.45,which is 16.92% down from its 52 week high and 244.44% up from its 52 week low.

What is InflaRx N.V.'s market capitalisation today?

InflaRx N.V. market capitalisation is $0.00T as on .

How to invest in InflaRx N.V. Stock (IFRX) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for InflaRx N.V. on INDmoney app. Click on Buy button. You can invest as low as $1.5 in InflaRx N.V. Shares that will get you 0.6122 shares as per InflaRx N.V. share price of $2.45 per share as on May 13, 2026 at 1:29 am IST.

What is the minimum amount required to buy InflaRx N.V. Stock (IFRX) from India?

Indian investors can start investing in InflaRx N.V. (IFRX) shares with as little as ₹95.618 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹956.18 in InflaRx N.V. stock (as per the Rupee-Dollar exchange rate as on ). Based on InflaRx N.V. share’s latest price of $2.45 as on May 13, 2026 at 1:29 am IST, you will get 4.0816 shares of InflaRx N.V.. Learn more about fractional shares .

What are the returns that InflaRx N.V. has given to Indian investors in the last 5 years?

InflaRx N.V. stock has given -12.28% share price returns and 29.61% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?